Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note released on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

RVNC has been the topic of a number of other research reports. Mizuho decreased their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research note on Tuesday, December 10th. Barclays decreased their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Monday, December 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Finally, HC Wainwright restated a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, Revance Therapeutics has an average rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Stock Up 1.0 %

RVNC opened at $3.09 on Friday. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $8.98. The business has a 50 day moving average of $3.91 and a 200-day moving average of $4.50. The stock has a market cap of $322.57 million, a price-to-earnings ratio of -1.60 and a beta of 0.86.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. As a group, analysts expect that Revance Therapeutics will post -1.57 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Certuity LLC acquired a new stake in shares of Revance Therapeutics in the 2nd quarter valued at $26,000. Vanguard Personalized Indexing Management LLC acquired a new position in Revance Therapeutics in the 2nd quarter valued at approximately $33,000. Hsbc Holdings PLC acquired a new position in shares of Revance Therapeutics during the second quarter worth $38,000. FORA Capital LLC acquired a new position in Revance Therapeutics during the 3rd quarter worth about $54,000. Finally, Creative Planning bought a new position in shares of Revance Therapeutics during the third quarter worth about $56,000. Institutional investors own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.